Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment
October 27 2023 - 1:40AM
Dow Jones News
By Adria Calatayud
Roche Holding said it received approval from the U.S. Food and
Drug Administration for Vabysmo as treatment of macular edema
following retinal vein occlusion, the drug's third indication.
The Swiss pharmaceutical giant said Friday that the approval was
based on two late-stage studies that demonstrated early and
sustained vision improvements.
Vabysmo is already approved for so-called "wet" age-related
macular degeneration and diabetic macular edema, Roche said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
October 27, 2023 01:25 ET (05:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
